- Multi-year strategic distribution partnership in dermatology, pulmonology and allergology brings together biosimilar expertise with broad specialist reach
- Biosimilars manufactured in Europe, paired with innovative devices, support modern care while strengthening the long-term sustainability of healthcare systems
Leiden, Netherlands / Dusseldorf, Germany / London, United Kingdom / Munich, Germany, 19 March 2026
– HAL Allergy Group (“HAL Allergy”), one of Europe’s leading specialists in the development, production and marketing of allergen immunotherapies for respiratory and venom allergies, and Advanz Pharma, a global pharmaceutical company with a strategic focus on biosimilars, specialty, hospital and rare disease medicines, headquartered in the United Kingdom with its German office in Munich, today announced a multi-year strategic distribution partnership.
The collaboration aims to sustainably expand access to modern, cost-effective biosimilar therapies for patients in Germany and Austria across dermatological, respiratory and allergological indications.
In recent years, biological therapies have significantly expanded treatment options across these therapeutic areas. At the same time, there is a growing need to ensure the long-term, economically sustainable integration of these innovative medicines into healthcare systems. In this context, Biosimilars play a key role in supporting the integration of biological therapies into clinical practice and contribute to the sustainability of healthcare systems. The partnership between HAL Allergy and Advanz Pharma comes at a time of growing momentum for biosimilars. As patents on key biologics expire, the treatment landscape is evolving, creating new options for patients, physicians and healthcare systems alike.
Against this backdrop, the two companies are joining forces to combine their complementary strengths. HAL Allergy brings its deep expertise in allergology and its strong presence among specialist physicians in these therapeutic areas. Advanz Pharma complements this with its international experience in commercialising specialised medicines and its growing role in the biosimilars segment, providing sustainably manufactured biosimilars produced in Europe alongside user-friendly delivery formats.
Dr Piero Sciotto, Vice President DACH & Managing Director at Advanz Pharma, said: “Biosimilars are a central pillar of our strategy in the DACH region, as they expand patient access to modern biological therapies while supporting more sustainable healthcare ecosystems. With our growing biosimilars pipeline in Germany and Austria, we are building a broad portfolio designed to address critical gaps in care, particularly in areas of high unmet need. Strategic partnerships such as our collaboration with HAL Allergy are a key part of this approach, combining our biosimilar expertise with a strong specialist presence, laying the foundation for broader access to innovative, patient-centred biosimilar therapies across the DACH region.”
Dr Dr Philip Böhme, CEO of HAL Allergy, added: “We welcome this partnership with Advanz Pharma, an established provider of specialised medicines, including biosimilars and complex generics. The collaboration brings together our long-standing global expertise in allergology with Advanz Pharma’s expertise in biologics. Together, we can further expand access to essential therapies for patients, while ensuring reliable and cost-effective care for both physicians and patients. This partnership is set to advance allergology and related therapeutic areas in a meaningful way.”
Dr Dr Philip Böhme, CEO of HAL Allergy, and Dr Piero Sciotto, Vice President DACH & Managing Director at Advanz Pharma, sign a multi-year strategic distribution partnership (from left to right).
About biosimilars
Biosimilars are highly similar versions of approved biologic medicines that offer the same safety, efficacy and quality as their complex reference products. They expand access to modern therapies and help relieve pressure on healthcare systems by enabling cost savings, thereby creating additional financial headroom for innovation.
With a growing number of biologics set to lose patent protection in the coming years, biosimilars have become an integral part of modern medicine. Their approval is subject to stringent regulatory requirements, and their safety and efficacy are demonstrated through clinical studies, ensuring the confidence of both physicians and patients.
About HAL Allergy
HAL Allergy is a leading biopharmaceutical company with over 60 years of experience in the development, GMP-certified production, and marketing of allergen immunotherapies. The company is headquartered at the Leiden Bio Science Park in the Netherlands, with a German subsidiary in Düsseldorf. Additionally, HAL Allergy operates in several European markets through its own subsidiaries and distributes its products worldwide. The company specializes in therapies for the causal treatment and prevention of allergic and atopic diseases, including hay fever, allergic asthma, house dust mite and animal dander allergies, as well as allergic reactions to bee and wasp stings. The product portfolio includes subcutaneous (SCIT) and sublingual (SLIT) allergen immunotherapies based on standardized allergen extracts and innovative, proprietary production processes. With a solid scientific foundation, ongoing clinical research, and a clear focus on patient well-being, HAL Allergy has established itself as a trusted partner for allergists and specialists throughout Europe.
About Advanz Pharma
ADVANZ PHARMA is a global pharmaceutical company with a strategic focus on biosimilars, specialty, hospital and rare disease medicines they depend on. Our headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialization partner network. ADVANZ PHARMA’s product portfolio and pipeline comprises innovative medicines, biosimilars & specialty generics and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Our ambition is to be a partner of choice for the commercialization of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia.
Media Contact HAL Allergy
Heike Milan
HAL Allergie GmbH
Phone: +49 (0)211 97765 56
Email: hmilan@hal-allergy.com
Hal Allergy – Medical Information
Phone: +49 (0)211 97765 70
Email: medwiss@hal-allergy.com
Media Contact Advanz Pharma
Caroline Bergmann / Eva Bauer
MC Services AG
Phone: +49 (0)211 529252-20
Email: advanz@mc-services.eu
Advanz Pharma – Medical Information
Phone (Germany): +49 (0)800 1802 091
Phone (Austria): +43 (0)800 298 022
Email: medicalinformation@advanzpharma.com